Austar Lifesciences Announces 2022 Interim Results

Benefiting from the Growth in the Business Segment of Liquid and Bioprocess System and the Increased Capability of Comprehensive Integrated Solutions,its Businesses Grew Steadily Revenue Increased by 29.1% to RMB 1,104 million  Operation Highlights (RMB'000) For the six months ended 30 June ...